yeah but they much further along in their clinical trials now and they have the support of novartis and there has been a huge increase in institutional support from some big institutions.
desperation! i love it. squeal shorts!!!
Keep squealing shorts!!!
The question you really should be asking is if their pipeline was not so great, why would NVS and TEVA partner with them and why would Orbimed buy a ton of shares last quarter along with other major institutions?
This must be your first time looking at biotechs. You do realize that often bios are valued on potential, not earnings. There are countless number of bio companies with market caps in the multi-billions with no revenues/earnings to speak of. You are obviously new to the game.